4-(4-Isopropylbenzyl)thiomorpholine

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 异戊烯醇脂质
• 英文名称: 4-(4-Isopropylbenzyl)thiomorpholine
• 英文别名: 4-[(4-propan-2-ylphenyl)methyl]thiomorpholine
• 化学式: C₁₄H₂₁NS
• 分子量: 235.39
• InChiKey: OMRDFYAADUYWGG-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.3
• 重原子数：
  16
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.57
• 拓扑面积：
  28.5
• 氢给体数：
  0
• 氢受体数：
  2

文献信息

• NOVEL TRIAZOLE COMPOUNDS THAT MODULATE HSP90 ACTIVITY
  申请人：SYNTA PHARMACEUTICALS CORP.

  公开号：US20150119395A1

  公开（公告）日：2015-04-30

  The present invention relates to novel triazole Hsp90 inhibitors that possess significant inhibitory activity against Hsp90, which are suitable for the treatment of hyperproliferative diseases such as cancer, infections, immune disorders, inflammation, and CNS related disorders. Furthermore, pharmaceutical compositions, including combination products, are also provided in the present application. Further provided are methods of using the pharmaceutical compositions and/or combination products.

  本发明涉及一种新型的三唑Hsp90抑制剂，具有显著的Hsp90抑制活性，适用于治疗高增殖性疾病，如癌症、感染、免疫障碍、炎症和中枢神经系统相关疾病。此外，本申请还提供了包括联合产品在内的制药组合物。还提供了使用制药组合物和/或联合产品的方法。
• TRIAZOLE DERIVATIVES AS HSP90 INHIBITORS
  申请人：Synta Pharmaceuticals Corp.

  公开号：US20150051203A1

  公开（公告）日：2015-02-19

  A compound of structural formula (I) or (II): as HSP90 inhibitors that possess significantly improved bioavailability over comparative compounds, which are suitable for the treatment of hyperproliferative diseases such as cancer, infections, immune disorders, inflammation, and CNS related disorders.

  化学结构式(I)或(II)的化合物，作为HSP90抑制剂具有明显改善的生物利用度，适用于治疗增殖过度性疾病，如癌症、感染、免疫障碍、炎症和中枢神经系统相关疾病。